Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care

By afschroeder • March 8, 2026

Brufsky AM, Finn RS, Metzger O, Goncalves R, Huang-Bartlett C, Sreenivasan S, Nur U, Davies J, Grigorenko A, Long GH. Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care. Breast Cancer Res Treat. 2026 Mar 7;216(2):22. doi: 10.1007/s10549-026-07935-3. PMID: 41793559; PMCID: PMC12967648.

Tags: Cyclin-dependent kinase 4/6, Hematology/Oncology, metastatic breast cancer, overall survival, Publications, real-world data, Target trial emulation

Related Posts

Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma

Colevas AD, Chin V, Park JJ, Adkins D, Phan M, Fang B, Forget F, Amorim J, Misiukiewicz K, Costa DA, Rainey N, Even C, Wong[...]

The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer

Leonhardt CS, Adham M, Bazarbashi S, Ben-Aharon I, Beets-Tan RGH, Boggi U, Brunner TB, Cellini F, Chiti A, Daamen L, De Bari B, De Dosso[...]

Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study

Yu HA, Tang KH, Markovets AA, Hartmaier R, Smith PE, Cho BC, De Langen AJ, Goldberg SB, Goldman JW, Le X, Iwama E, Cosaert J,[...]